FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Coronary Drug-Eluting Stent
PMA: P110010
·
Supplement: S207
·
Decision Mar 2, 2023
Classifications
1
FEI Numbers
32
Registration Numbers
32
Basic Information
- Device Name
- Coronary Drug-Eluting Stent
- Trade Name
- Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, Promus Elite Everolimus-Eluting Platinum Chro
- PMA Number
- P110010
- Supplement Number
- S207
- Device Class
- FDA Class 3
- Product Code
- NIQ
- Generic Name
- Coronary drug-eluting stent
- Medical Specialty
- Unknown
- Advisory Committee
- Cardiovascular
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- March 2, 2023
- Date Received
- December 7, 2022
- Supplement Type
- Real-Time Process
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for the introduction of an alternative resin material (ReZilok Rx 101) supplied by existing BSC-approved supplier Compounding Solutions.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| NIQ | Coronary Drug-Eluting Stent | FDA class 3 | Unknown |